Spots Global Cancer Trial Database for stage iiia primary peritoneal cavity cancer
Every month we try and update this database with for stage iiia primary peritoneal cavity cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | NCT00601406 | Breast Cancer Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... Prostate Cancer Sarcoma Vaginal Cancer Vulvar Cancer | gene expression... gene rearrangem... polymorphism an... laboratory biom... radiation thera... | - | National Cancer Institute (NCI) | |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02122185 | Brenner Tumor Malignant Ascit... Malignant Pleur... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Ovaria... Stage IV Primar... | metformin hydro... placebo Chemotherapy | 18 Years - | University of Chicago | |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | NCT00562640 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim therapeutic aut... cyclophosphamid... laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | NCT00305838 | Fallopian Tube ... Ovarian Cancer Primary Periton... | tamoxifen citra... diagnostic labo... | - | National Cancer Institute (NCI) | |
| Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00838656 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin gemcitabine hyd... paclitaxel | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | NCT00601406 | Breast Cancer Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... Prostate Cancer Sarcoma Vaginal Cancer Vulvar Cancer | gene expression... gene rearrangem... polymorphism an... laboratory biom... radiation thera... | - | National Cancer Institute (NCI) | |
| Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | NCT00075712 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel adjuvant therap... conventional su... neoadjuvant the... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00388037 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | sunitinib malat... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | NCT00305838 | Fallopian Tube ... Ovarian Cancer Primary Periton... | tamoxifen citra... diagnostic labo... | - | National Cancer Institute (NCI) | |
| CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | NCT00305838 | Fallopian Tube ... Ovarian Cancer Primary Periton... | tamoxifen citra... diagnostic labo... | - | National Cancer Institute (NCI) | |
| Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission | NCT00693342 | Fallopian Tube ... Ovarian Cancer Primary Periton... | immunological a... polyvalent anti... | 18 Years - 120 Years | GOG Foundation | |
| Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | NCT00303888 | Fallopian Tube ... Ovarian Cancer Primary Periton... | docetaxel idronoxil placebo | 18 Years - 120 Years | Yale University | |
| Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | NCT01764802 | Ovarian Sarcoma Ovarian Stromal... Stage I Uterine... Stage I Vaginal... Stage I Vulvar ... Stage IA Cervic... Stage IA Endome... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IA Primar... Stage IB Cervic... Stage IB Endome... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IB Primar... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage IC Primar... Stage II Endome... Stage II Gestat... Stage II Uterin... Stage II Vagina... Stage II Vulvar... Stage IIA Cervi... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIA Prima... Stage IIB Cervi... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIB Prima... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage IIC Prima... Stage III Gesta... Stage III Uteri... Stage III Vagin... Stage III Vulva... Stage IIIA Cerv... Stage IIIA Endo... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Cerv... Stage IIIB Endo... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Endo... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Breast Cancer | behavioral, psy... behavioral, psy... | 21 Years - 80 Years | Ohio State University Comprehensive Cancer Center | |
| Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00897039 | Fallopian Tube ... Ovarian Cancer Primary Periton... | flow cytometry immunohistochem... | - | National Cancer Institute (NCI) | |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | NCT00562640 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim therapeutic aut... cyclophosphamid... laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | NCT00483782 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bevacizumab carboplatin paclitaxel questionnaire a... study of socioe... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | NCT00045461 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin ifosfamide hyperthermia tr... | 18 Years - 65 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
